Teva to acquire MicroDose for up to $165 million

JERUSALEM — Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.

Teva said it would acquire MicroDose Therapeutx for $40 million, plus up to $125 million in milestone payments and sales milestones and royalties from its lead product, MDT-637, an inhaled treatment for respiratory syncytial virus, or RSV.

"I am thrilled tha tTeva can now count the exciting MicroDose products and technologies amongst our growing respiratory portfolio," Teva chief scientific officer and president for global research and development Michael Hayden said. "The MicroDose platform is both simple and attractive, and their addition will help us to address the unmet needs of the youngest and oldest patients, who have a requirement for a better way of taking the medicines they rely upon."